Financial Performance - Oncternal Therapeutics reported a net loss of $13.6 million for the six months ended June 30, 2021, with an accumulated deficit of $96.4 million[100]. - As of June 30, 2021, Oncternal had cash and cash equivalents of $103.7 million, which is expected to fund operations for at least the next twelve months[104]. - Net cash used in operating activities for the six months ended June 30, 2021, was $13.6 million, resulting from a net loss of $13.6 million[127]. - Grant revenue for the three months ended June 30, 2021, was $0.9 million, an increase of $0.3 million from $0.6 million in 2020, primarily due to higher research and development subaward costs[115]. - Total operating expenses for the three months ended June 30, 2021, were $8.6 million, an increase of $2.4 million from $6.2 million in 2020[114]. - Research and development expenses for the six months ended June 30, 2021, were $9.1 million, an increase of $2.6 million from $6.5 million in 2020, driven by a $1.6 million increase in direct product candidate costs[121]. - General and administrative expenses for the six months ended June 30, 2021, were $6.2 million, an increase of $1.2 million from $5.0 million in 2020, primarily due to higher personnel and professional costs[124]. Funding and Capital Requirements - The company has raised approximately $125.0 million from common stock issuance and $49.0 million from convertible preferred stock issuance as of June 30, 2021[99]. - The company anticipates needing substantial additional funding to support ongoing operations and business strategy[102]. - The company anticipates needing to raise substantial additional capital in the future to fund ongoing operations and development activities[111]. - Future capital requirements will depend on various factors, including the costs and timing of clinical trials and regulatory reviews[130]. - There is no assurance that the company will be able to obtain financing on acceptable terms, which could impact product development and commercialization efforts[131]. - The company may face dilution of stockholder ownership if additional capital is raised through debt or equity securities[131]. Clinical Development and Trials - Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of B-cell lymphoid malignancies, with a target enrollment of at least 20 patients for the MCL cohort[96][97]. - The FDA has granted orphan drug designations for cirmtuzumab for MCL and CLL, and for TK216 for Ewing sarcoma[95]. - Cirmtuzumab's Phase 1/2 trial results were presented at the American Society of Clinical Oncology 2021 Annual Meeting, indicating encouraging interim results[96]. - The ongoing COVID-19 pandemic has impacted clinical trial timelines, with delays expected for the ROR1 CAR-T therapy's first-in-human dosing to the first half of 2022[105]. - Direct expenses for cirmtuzumab increased by $0.3 million for the six months ended June 30, 2021, primarily due to increased clinical trial costs[122]. Accounting and Financial Reporting - The company considers its critical accounting policies related to research and development expenses and revenue recognition, with no material changes during the six months ended June 30, 2021[136]. - The financial statements are prepared in accordance with generally accepted accounting principles, requiring estimates and judgments that affect reported amounts[134]. - Actual results may differ from estimates based on various assumptions or conditions[135]. - The company has not engaged in any off-balance sheet arrangements during the periods presented[137]. Regulatory and Compliance - As of June 30, 2021, the company was unable to estimate the timing or likelihood of achieving specified development, regulatory, and commercial milestones related to its license agreements[132]. - The company has payment obligations under license agreements that are contingent upon future events, including royalty payments for product sales developed under those agreements[132]. - The company enters into contracts with clinical trial sites and supply manufacturers, which generally allow for termination after a notice period[133]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[139].

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President & Chief Executive Officer Edwina Baskin-Bey - Acting Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Robert Burns - H.C. Wainwright Kumar Raja - Brookline Capital Market Operator Good day ladies and gentlemen and welcome to Oncternal's Therapeutics Inc. First Quarter 2021 Financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-50549 Oncternal Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 62-1715807 (State or other jurisdiction of incorporation or organization) ...

ONCT Corporate Presentation March 2021 > ONCTERNAL > therapeutics™ TARGETING CANCER New Science. New Cancer Therapies. New Hope. Company Overview – March 2021 FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements (including within the meaning of §21E of the U.S. Securities Exchange Act of 1934, as amended, and § 27A of the U.S. Securities Act of 1933, as amended). Forward looking statements, which generally include statements regarding goals, plans, intentions and expectations, ar ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2020 Earnings Conference Call March 11, 2021 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President & Chief Executive Officer Edwina Baskin-Bey - Acting Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Securities Operator Greetings, and welcome to Oncternal's Therapeutics Incorporated Fourth Quarter 2020 Financial Results Call. [Operator Instructions] As a reminder this conference is being r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-50549 Oncternal Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) Delaware 62-1715807 (IRS Emp ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Richard Vincent – Chief Financial Officer Jim Breitmeyer – President & Chief Executive Officer Frank Hsu – Chief Medical Officer Conference Call Participants Robert Burns – H.C. Wainwright Operator Greetings, and welcome to Oncternal's Q2 Financial Results Call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the conference over to our ho ...

ONCT Corporate Presentation May 7, 2020 O O ONCTERNAL O therapeutics™ TARGETING CANCER New Science. New Cancer Therapies. New Hope. Company Overview – May 7, 2020 FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements (including within the meaning of §21E of the U.S. Securities Exchange Act of 1934, as amended, and § 27A of the U.S. Securities Act of 1933, as amended). Forward looking statements, which generally include statements regarding goals, plans, intentions and expectations ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants | --- | |---------------------------------------------------------------| | | | Richard Vincent - CFO Jim Breitmeyer - President and CEO | | Frank Hsu - Chief Medical Officer | | Conference Call Participants | | | | Hartaj Singh - Oppenheimer Carl Byrnes - Northland Securities | | Robert Burns - H.C. Wainwright | Operator Greetings, and welcome to the Oncternal Therapeutics Incorporated Fi ...

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2019 Results Conference Call March 16, 2020 4:30 PM ET Company Participants | --- | |------------------------------------------------------------| | | | Richard Vincent - CFO | | Dr. Jim Breitmeyer - President and CEO | | Dr. Frank Hsu - Chief Medical Officer | | Conference Call Participants | | Hartaj Singh - Oppenheimer | | Matt Kaplan - Ladenburg Carl Byrnes - Northland Securities | Operator Greetings, ladies and gentlemen, and welcome to the Oncternal Therap ...